Patients aged @ to @ years with chronic plaque-type psoriasis , a minimum Physician Global Assessment score of @ ( higher scores indicate more severe disease ) , and a psoriatic plaque of at least @ cm were randomized in a @:@ fashion to receive subcutaneous adalimumab or oral methotrexate .